The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Welcome to The Aggressive & Diffuse Large B-Cell Lymphoma Channel
VJHemOnc shares important updates on aggressive & diffuse large B-cell lymphoma, a common lymphoid malignancy in adults accounting for 30% of malignant lymphomas. The Aggressive & Diffuse Large B-Cell Lymphoma Channel provides unique perspectives from distinguished experts around the world in the form of video interviews, podcasts, and roundtable discussions.
Explore the latest research into novel therapies including CAR-T cells, immunomodulators, and antibody-drug conjugates on The Aggressive & Diffuse Large B-Cell Lymphoma Channel.
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
Diamond Supporter
Gold Supporter
Silver Supporter
Bronze Supporter
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.
